Ernesto Wasserman
Merus B.V. · AAIOncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ernesto Wasserman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:26 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03321981 · MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.Merus B.V. · completed · Breast Cancer Metastatic · study director
- Ph1NCT00551512 · Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid TumorsCanBas Co. Ltd. · completed · Cancer, Solid Tumors · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:26 UTC. The ranking covers the 200 most relevant of 27 PubMed records, and a shared surname and initials can bring in a namesake. All 27 on PubMed
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2017396 citationsRCR 12.9
- Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer.N Engl J Med · 2025122 citationsRCR 24.2
- Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.J Clin Oncol · 1999108 citationsRCR 3.1
- Contributions of specific cell information to judgments of interevent contingency.J Exp Psychol Learn Mem Cogn · 199065 citationsRCR 3.5
- Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study.Int J Radiat Oncol Biol Phys · 200258 citationsRCR 1.4
- Phase I Study of the Prolactin Receptor Antagonist LFA102 in Metastatic Breast and Castration-Resistant Prostate Cancer.Oncologist · 201652 citationsRCR 1.8
- Randomized study of different anti-stigma media.Patient Educ Couns · 200850 citationsRCR 2.1
- 44 citationsRCR 1.1
- 44 citationsRCR 1.5
- Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma.J Transl Med · 201034 citationsRCR 0.8